Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Share-based Compensation: 2017-2024

Historic Share-based Compensation for Monopar Therapeutics (MNPR) over the last 7 years, with Dec 2024 value amounting to $4.6 million.

  • Monopar Therapeutics' Share-based Compensation rose 16.78% to $283,713 in Q3 2020 from the same period last year, while for Sep 2020 it was $1.3 million, marking a year-over-year increase of 30.91%. This contributed to the annual value of $4.6 million for FY2024, which is 139.86% up from last year.
  • Monopar Therapeutics' Share-based Compensation amounted to $4.6 million in FY2024, which was up 139.86% from $1.9 million recorded in FY2023.
  • In the past 5 years, Monopar Therapeutics' Share-based Compensation ranged from a high of $4.6 million in FY2024 and a low of $1.3 million during FY2020.
  • For the 3-year period, Monopar Therapeutics' Share-based Compensation averaged around $2.7 million, with its median value being $1.9 million (2023).
  • Data for Monopar Therapeutics' Share-based Compensation shows a peak YoY skyrocketed of 139.86% (in 2024) over the last 5 years.
  • Over the past 4 years, Monopar Therapeutics' Share-based Compensation (Yearly) stood at $1.3 million in 2020, then reached $1.6 million in 2022, then increased by 15.63% to $1.9 million in 2023, then spiked by 139.86% to $4.6 million in 2024.